INmune Bio, Inc. (INMB)
NASDAQ: INMB · Real-Time Price · USD
4.560
-0.150 (-3.18%)
At close: Nov 20, 2024, 4:00 PM
4.300
-0.260 (-5.70%)
After-hours: Nov 20, 2024, 5:10 PM EST
INmune Bio Employees
As of December 31, 2023, INmune Bio had 17 total employees, including 11 full-time and 6 part-time employees. The number of employees increased by 7 or 70.00% compared to the previous year.
Employees
17
Change (1Y)
7
Growth (1Y)
70.00%
Revenue / Employee
$2,471
Profits / Employee
-$2,427,765
Market Cap
101.11M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Akoya Biosciences | 330 |
| Adagene | 174 |
| Century Therapeutics | 165 |
| Inovio Pharmaceuticals | 122 |
| Fractyl Health | 102 |
| Assembly Biosciences | 65 |
| Leap Therapeutics | 54 |
| Tiziana Life Sciences | 9 |
INMB News
- 20 days ago - INmune Bio, Inc. (INMB) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 20 days ago - INmune Bio Inc. Announces Third Quarter 2024 Results and Provides Business Update - GlobeNewsWire
- 24 days ago - INmune Bio Inc. to Host Webinar on Cognitive Testing Using EMACC and CDR-SB - GlobeNewsWire
- 27 days ago - INmune Bio Inc. Announces Publication in Cell Reports Demonstrating XPro™ Promotes Remyelination - GlobeNewsWire
- 4 weeks ago - INmune Bio Inc. to Report Third Quarter 2024 Financial Results and Provide Corporate Update on October 31, 2024 - GlobeNewsWire
- 5 weeks ago - INmune Bio Inc. to Participate in the Maxim Healthcare Virtual Summit - GlobeNewsWire
- 7 weeks ago - INmune Bio: NK Cell Therapy INKmune For mCRPC Is Another Shot On Goal - Seeking Alpha
- 2 months ago - INKmune™ Demonstrates Excellent Safety and Increased NK-Cell Activity in First Dosing Cohort - GlobeNewsWire